| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/06/2004 | US6716962 Contacting the antibiotic with a divalent metal ion and an organic solvent, to extract the lipopeptide antibiotic into the solvent; and contacting the extract of the lipopeptide antibiotic with acid. |
| 04/06/2004 | US6716961 Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone |
| 04/06/2004 | US6716869 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide |
| 04/06/2004 | US6716860 Azo amino acids derivatives |
| 04/06/2004 | US6716843 Inhibitor of dipeptidyl-peptidase iv |
| 04/06/2004 | US6716818 Caspase inhibitors and the use thereof |
| 04/06/2004 | US6716817 Method of treatment of female infertility |
| 04/06/2004 | US6716816 Dyslipidemia, hypercholesterolemia, cardiovascular disease, atherosclerosis, restenosis, and other disorders such as septic shock. |
| 04/06/2004 | US6716815 Comprises whey/soy protein, casein-polypeptide, fatty acid, and insoluble vegetable/fruit fiber which stimulates cholecystokinin levels for better regulation of glucose and insulin levels following meal consumption; diabetes |
| 04/06/2004 | US6716813 Administering protein |
| 04/06/2004 | US6716812 Calcitonin promotes fertilizing ability in mammalian sperm and is useful for treatment of conditions of low fertility in humans and animals |
| 04/06/2004 | US6716811 Low white blood cell titer |
| 04/06/2004 | US6716627 Mucin 1, transmembrane may help to frustrate infection in the mammary gland (mastitis) and possibly in other sites in the body (such as bladder and kidney infections) by competitively inhibiting the binding of microorganisms |
| 04/06/2004 | US6716624 GSK3 polypeptides |
| 04/06/2004 | US6716623 Compositions and methods for identifying antigens which elicit an immune response |
| 04/06/2004 | US6716621 Isolated DNA or gene responsible for Parkinson's disease |
| 04/06/2004 | US6716613 Metalloprotease having aggrecanase activity |
| 04/06/2004 | US6716607 Chicken interferon gene and novel recombinant DNA |
| 04/06/2004 | US6716606 For use in hematopoietic therapy; for arresting proliferation of leukemic cells |
| 04/06/2004 | US6716603 Nucleic acids encoding a chloride channel protein |
| 04/06/2004 | US6716600 Persephin and related growth factors |
| 04/06/2004 | US6716597 Methods and products for regulating cell motility |
| 04/06/2004 | US6716587 Antiinflammatory |
| 04/06/2004 | US6716586 Insulin-like growth factor agonist molecules |
| 04/06/2004 | US6716585 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis |
| 04/06/2004 | US6716583 Methods of producing nucleic acid ligands |
| 04/06/2004 | US6716576 Method of assaying Neutrokine-α mRNA level |
| 04/06/2004 | US6716575 Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| 04/06/2004 | US6716449 Dosage form; antagonist to attenuate a side effect of said opioid agonist; analgesia for at least about eight hours when administered to human patients |
| 04/06/2004 | US6716441 Article comprising dispensing means with applied release composition including selected skin care active, release agent and barrier protectant; oleaginous, partially transferable to wearer's skin; contains ethoxylated c20-c40 fatty alcohol |
| 04/06/2004 | US6716436 In combination with cosmetically acceptable excipient at least one nitric oxide precursor compound which is l-arginine analogue or one of its derivatives or salts |
| 04/06/2004 | US6716430 Moderating immunology response |
| 04/06/2004 | US6716429 Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain |
| 04/06/2004 | US6716428 Synthetic peptides mimick epitope regions of hormones such as human chorionic gonadotropin can be conjugated to carrier; contraceptives, anticarcinogenic agents |
| 04/06/2004 | US6716427 Method for treating hypocalcemia |
| 04/06/2004 | US6716426 Administering xanthine oxidase conjugated to polyoxyethylene glycol and hypoxanthine or xanthine |
| 04/06/2004 | US6716425 Administering to mammal cells modified by in vitro treatment with cytokine and gamma irradiation at dosage to irreversible arrest proliferation but not interfere with cytotoxicity |
| 04/06/2004 | US6716423 Diagnostic assays for detection of neospora infections in cattle; administering immunogen; breeding |
| 04/06/2004 | US6716208 Implantable device and use therefor |
| 04/06/2004 | CA2269077C Keratinocyte growth factor-2 products |
| 04/06/2004 | CA2196296C Production of tissue factor pathway inhibitor |
| 04/06/2004 | CA2147372C Multidrug resistance gene |
| 04/06/2004 | CA2091134C Therapeutic agent for threatened abortion |
| 04/06/2004 | CA2089563C Oligonucleotide modulation of cell adhesion |
| 04/06/2004 | CA2036592C Therapeutic agent for diabetic gangrene |
| 04/06/2004 | CA2010321C Lymphocyte-associated cell surface protein |
| 04/01/2004 | WO2004027079A2 Nuclear factor of activated t cells receptor |
| 04/01/2004 | WO2004027073A1 Modified adenoviral vectors for use in vaccines and gene therapy |
| 04/01/2004 | WO2004027064A2 Ghrh analogues |
| 04/01/2004 | WO2004027063A1 Use of sirnas for gene silencing in antigen presenting cells |
| 04/01/2004 | WO2004027062A2 Functional correction of the -786c/t variance of the human enos gene |
| 04/01/2004 | WO2004027044A2 Triplex hairpin ribozyme |
| 04/01/2004 | WO2004027041A2 P. ariasi polypeptides, p. perniciosus polypeptides and methods of use |
| 04/01/2004 | WO2004027033A2 Lentiviral vector-mediated gene transfer and uses thereof |
| 04/01/2004 | WO2004027026A2 Improved methods for preparing highly active april ligand polypeptides |
| 04/01/2004 | WO2004027020A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 04/01/2004 | WO2004026909A2 Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof |
| 04/01/2004 | WO2004026907A2 Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals |
| 04/01/2004 | WO2004026905A2 Transporter/channel proteins |
| 04/01/2004 | WO2004026904A1 Rfamide-related peptide precursor proteins and rfamide peptides |
| 04/01/2004 | WO2004026897A1 Wt1 substitution peptides |
| 04/01/2004 | WO2004026896A2 Hcv ns-3 serine protease inhibitors |
| 04/01/2004 | WO2004026895A2 Gd2 ligands |
| 04/01/2004 | WO2004026894A2 Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity |
| 04/01/2004 | WO2004026814A2 Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
| 04/01/2004 | WO2004026406A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 04/01/2004 | WO2004026345A1 Control of nitric oxide bioactivity by perfluorocarbons |
| 04/01/2004 | WO2004026335A1 Pharmaceutical composition comprising carriers for products |
| 04/01/2004 | WO2004026334A1 Antimicrobial composition and method for use |
| 04/01/2004 | WO2004026333A1 Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-ϝ |
| 04/01/2004 | WO2004026332A1 Methods of increasing platelet and hematopoietic stem cell production |
| 04/01/2004 | WO2004026331A1 Peptides inhibiting specific cleaving activities of presenilins |
| 04/01/2004 | WO2004026330A1 Methods and preparations for curing critically ill patients |
| 04/01/2004 | WO2004026329A1 Peptides and related molecules that modulate nerve growth factor activity |
| 04/01/2004 | WO2004026328A1 Compstatin analogs with improved activity |
| 04/01/2004 | WO2004026327A1 Homing peptides to receptors of heart vasculature |
| 04/01/2004 | WO2004026326A2 Antigen uptake receptor for candida albicans on dendritic cells |
| 04/01/2004 | WO2004026322A1 Method and preparation for preventing casualty caused by iodine radionuclides and optimising iodine metabolism in a postprophylaxis period |
| 04/01/2004 | WO2004026285A2 Compositions and methods for treating heart disease |
| 04/01/2004 | WO2004026279A1 Effervescent formulations of oxytocin |
| 04/01/2004 | WO2004026278A1 Copolymer and hemoprotein based novel compounds and uses thereof |
| 04/01/2004 | WO2004026264A2 Novel aromatic compounds possessing antifungal or antibacterial activity |
| 04/01/2004 | WO2004026228A2 Method for reducing morbidity and mortality in critically ill patients |
| 04/01/2004 | WO2004026189A2 Collagen-based materials and methods for augmenting intervertebral discs |
| 04/01/2004 | WO2004026118A2 Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| 04/01/2004 | WO2004018681A3 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof |
| 04/01/2004 | WO2004013631A3 Compositions and methods for diagnosis and therapy of cancer |
| 04/01/2004 | WO2004013298A3 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections |
| 04/01/2004 | WO2004007723A3 Genes |
| 04/01/2004 | WO2004005473A3 Hcv fusion proteins with modified ns3 domains |
| 04/01/2004 | WO2004005460A3 Antisense modulation of hmg-coa reductase expression |
| 04/01/2004 | WO2004003165A9 Novel polynucleotide and polypeptide sequences and uses thereof |
| 04/01/2004 | WO2004003008A3 Peptides for inducing apoptosis in tumor cells |
| 04/01/2004 | WO2004002401A3 Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents |
| 04/01/2004 | WO2004000354A3 Method of treating the syndrome of lipodystrophy |
| 04/01/2004 | WO2003106659A3 Aptamer-toxin molecules and methods for using same |
| 04/01/2004 | WO2003105767A3 Antifungal parenteral products |
| 04/01/2004 | WO2003105760A3 Treatment of non-alcoholic fatty liver disease |
| 04/01/2004 | WO2003105754A3 Antisense modulation of vegf-b expression |
| 04/01/2004 | WO2003104402A3 Non-polymeric hematopoietic cell clots for delivery of active agents |